Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Article

J App Pharm Sci. 2020; 10(2): 108-111


Pharmacokinetic drug–drug interaction study between clindamycin and cyclosporin in rabbits

Issam Mohammed Abushammala, Lama Attef El Gussein, Badea Elzaman Zomlot, Kamal Fakher Abushammalleh, Mohammed Mahmoud Taha, Mohammed Yousef Miqdad.

Abstract
Abstract: Cyclosporine A (CSA) is an immunosuppressant drug, metabolized mainly by CYP3A4 that is one of the Cytochrome P450 enzymes. Clindamycin (CLN) is a lincosamide antibiotic, inducing CYP3A4 activity in vitro and thereby may alter CSA pharmacokinetics (PK). The current research was performed to investigate the PK parameters changes of CSA up on co-administrating with CLN in healthy male rabbits. Twelve healthy male rabbits randomly were selected and divided into two groups: Control set (n=6) in which the rabbits were received oral normal saline CSA solution (10 mg/kg/day), meanwhile rabbits in the test group (n=6) were treated with oral normal saline CSA solution (10 mg/kg/day) concomitantly with normal saline solution of CLN (8 mg/kg/day) at the same time for 7 days. Blood samples (2 mL) were collected and CSA concentrations were measured in whole blood at the predetermined time points by using Chemiluminescenct Immunoassay (CLIA) detection kit. PK proļ¬les of CSA for both groups in the control and test groups including Cmax, tmax, AUC0-24, AUC0-āˆž, t½ and Ke were compared. The results showed a statistically insignificant differences in the PK parameters of CSA alone or combined with CLN with P>0.05. In conclusion, it has been found that CLN does not affect the CSA PK. Further confirmation of our findings is requiered in humans before these results can be applied in patient care.

Key words: Cyclosporine, clindamycin, drug interaction, pharmacokinetic, CYP3A4



Similar Articles

Optogenetic activation of intracellular signaling based on light-inducible protein-protein homo-interactions.
Huang P, Zhao Z, Duan L
Neural regeneration research. 2022; 17(1): 25-30

3D and 4D Tumorigenesis Model for the Quantitative Analysis of Cancer Cell Behavior and Screening for Anticancer Drugs.
Wessels D, Lusche DF, Voss E, Soll DR
Methods in molecular biology (Clifton, N.J.). 2022; 2364(): 299-318

Turbidity-Based MIC Assay and Characterization of Spontaneous Drug Resistant Mutants in Mycobacterium ulcerans.
Thomas SS, Kalia NP, Pethe K
Methods in molecular biology (Clifton, N.J.). 2022; 2387(): 209-217

Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.
Converse PJ, Almeida DV, Nuermberger EL
Methods in molecular biology (Clifton, N.J.). 2022; 2387(): 195-207

In Vitro Assessment of Drug Activity Against Mycobacterium ulcerans.
Komm OD, Almeida DV, Converse PJ, Nuermberger EL
Methods in molecular biology (Clifton, N.J.). 2022; 2387(): 189-194


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.



ScopeMed Web Sites